ViewRay

ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.

ViewRay has continued growth in order momentum. Its stock price has moved sideways into the new year, adding another attractive entry point.

ViewRay: Sales, Order Momentum Ratcheting Higher

DENVER , Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Monday, February 27, 2023 at 4:30 p.m.

ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023

CLEVELAND , Jan. 20, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors (the "Board"), effective as of January 20, 2023. The Company has also agreed that the Board will appoint Mr.

ViewRay Enters into Cooperation Agreement with Hudson Executive Capital

MIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT DENVER , Jan. 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy – delivered with MRIdian – to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity.

Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

DENVER , Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change.

ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China DENVER , Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. Chindex, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment

Immediate order of one system with ability to purchase an additional three systems DENVER , Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian MR-Guided Radiation Therapy System as part of a master agreement for the purchase of up to four systems, and will be the first in Ohio at a research and teaching hospital to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, kidney, gynecological, lung, liver, breast, brain, spine, and oligometastatic cancers. UH Seidman Cancer Center is part of the NCI-designated Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.

University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems

Revised FY22 revenue guidance with management more confident on the lower end of range. Backlog continues to grow, ending 26% higher to $350mm for the third quarter.

ViewRay: Revise Thesis To Buy, Multiple Upside Targets In Place

Facility includes senior secured term loan of up to $100 million and a revolving line of credit of up to $25 million DENVER , Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced that it has entered into a new five-year loan facility agreement with MidCap Financial and Silicon Valley Bank (the "Agreement"). The Agreement consists of a term loan of up to $100 million and a revolving line of credit of up to $25 million.

ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility

DENVER , Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 9:30 a.m.

ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference

DENVER , Nov. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 2:25 p.m.

ViewRay® to Present at the Stifel 2022 Healthcare Conference

ViewRay, Inc. (NASDAQ:VRAY ) Q3 2022 Results Conference Call November 1, 2022 5:00 PM ET Company Participants Matt Harrison - Director, IR Scott Drake - President & CEO Zach Stassen - CFO Dr. Paul Strong - VP of Clinical Affairs Conference Call Participants Jason Bednar - Piper Sandler Rick Wise - Stifel Marie Thibault - BTIG Mike Ott - Opp Co Young Li - Jefferies Operator Good day and thank you for standing by. Welcome everyone to the ViewRay Third Quarter 2022 Earnings Call.

ViewRay, Inc. (VRAY) Q3 2022 Earnings Call Transcript

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

DENVER , Nov. 1, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third  Quarter 2022 Highlights Total revenue for the third quarter 2022 was approximately $26.5 million, primarily from four revenue units, compared to approximately $19.2 million, primarily from three revenue units, in the third quarter of 2021.

ViewRay Announces Third Quarter 2022 Results

Final outcomes comparing acute grade ≥2 genitourinary toxicity following MRI- vs. CT-guided prostate SBRT presented at ASTRO 2022 DENVER , Oct. 27, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the final primary endpoint results from the phase III randomized single-center MIRAGE trial were presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held October 23-26, 2022, at the Henry B.

MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

Study's primary objective of low grade 3+ toxicity was met; exploration of secondary outcomes underway to confirm local control rates and patient outcomes with MRIdian SMART DENVER , Oct. 24, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the findings from the first Phase II prospective international multi-institutional study to deliver ablative doses of radiation to pancreatic cancer patients will be presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio.

ViewRay Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

Clinical outcome oral presentations on SMART Pancreas and MIRAGE prostate studies DENVER , Oct. 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company's MRIdian® MRI-Guided Radiation Therapy System will be featured at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held October 23-26, 2022, at the Henry B. González Convention Center in San Antonio, Texas.

MRIdian Clinical Studies and Initial MRIdian A3i Clinical Experience to be Highlighted at ASTRO 2022

Prospective multi-center international randomized controlled trial will compare 2-year overall survival in pancreatic cancer patients receiving post-chemotherapy ablative MRIdian SMART vs. chemotherapy alone DENVER , Oct. 18, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the launch of a phase III randomized controlled trial titled "Locally Advanced Pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy" – also known as LAP-ABLATE.

ViewRay Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

DENVER, Oct. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of third quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Tuesday, November 1, 2022, at 5:00 p.m.

ViewRay Announces Conference Call for Third Quarter 2022 Financial Results to be Held After Market on November 1, 2022

Becomes First Cancer Center in Upstate New York to offer the Advanced Precision of MRIdian® MRI-Guided Radiation  Therapy DENVER , Oct. 6, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that SUNY Upstate Cancer Center in Syracuse, New York has selected MRIdian MRI-Guided Radiation Therapy System and will be the first in Upstate New York to offer the precision of MRIdian's advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, lung, liver, breast, and oligometastatic cancers. SUNY Upstate Cancer Center is the region's most comprehensive resource for cancer care and offers the most advanced outpatient treatment, clinical research studies, and support services all in one convenient location.

SUNY Upstate Cancer Center Chooses ViewRay's MRI-Guided Radiation Therapy System to Treat Cancer Patients

Italian hospital reaches patient milestone in less than three years using MRIdian's real-time, on-table adaptive capabilities DENVER , Oct. 4, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that San Pietro Fatebenefratelli Hospital in Rome has treated its 1,000th patient with MRIdian® MRI-guided radiation therapy. The center reached the patient milestone in less than three years by leveraging MRIdian to treat a wide variety of patients including those with complex and hard to treat tumors, demonstrating the system's efficiency and clinical value.

San Pietro Fatebenefratelli Hospital Treats its 1,000th Patient with MRIdian® MRI-Guided Radiation Therapy

DENVER , Oct. 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today plans to host an Investor Day on Thursday, November 17, 2022, at 8:00 a.m. Eastern Time in New York City, NY.

ViewRay to host Investor Day

First MRIdian system to be installed at MD Anderson main campus at the Texas Medical Center in Houston DENVER , Sept. 20, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University of Texas MD Anderson Cancer Center in Houston, Texas purchased a MRIdian® MR-Guided Radiation Therapy System.

MD Anderson Cancer Center Selects ViewRay to Expand MR-Guided Radiation Therapy Program

DENVER , Sept. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference.

ViewRay® to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

New agreement expands access to precision radiotherapy to more cancer patients in the UK DENVER , Sept. 8, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that GenesisCare, the largest global provider of cancer services across the USA, UK, Spain and Australia, has purchased two additional MRIdian MRI-guided radiation therapy systems for installation at new-build comprehensive cancer centres in Guildford and Birmingham.

GenesisCare Purchases Two Additional ViewRay MRIdian MRI-guided Radiotherapy Systems for Guildford and Birmingham Projects, Doubling United Kingdom Footprint to Four Systems

News for ViewRay Stock (VRAY)